vimarsana.com

Latest Breaking News On - Antony mattessich - Page 7 : vimarsana.com

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U S Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U S Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U S Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and afliber.

Ocular Therapeutix sinks on missed Q3 earnings

Ocular Therapeutix (NSDQ:OCUL) this week posted third-quarter results that missed the overall consensus on Wall Street.

Ocular Therapeutix™ Announces Interim 7-month Data from U S Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Ocular Therapeutix™ Announces Interim 7-month Data from U S Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.